Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mitorx Therapeutics Limited has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and is located in 1 distinct art unit. This indicates that the company's current prosecution efforts are focused on a single technical matter within a specific administrative group.
O DELL, DAVID K is the busiest examiner for the company, currently handling 1 pending office action. This represents the total number of pending office actions for the portfolio. With 1 pending office action and 1 distinct examiner, the company's immediate success in the Biotechnology & Pharmaceuticals area depends on the specific feedback and requirements of this one individual. This concentration within 1 distinct art unit simplifies the management of the portfolio by eliminating the need to reconcile conflicting examiner requirements across different applications. The 1 pending office action is the only active matter currently recorded.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18691650 | IDEBENONE DERIVATIVES AND THEIR USE IN TREATING PLANTS | O DELL, DAVID K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18691650 | IDEBENONE DERIVATIVES AND THEIR USE IN TREATING PLANTS | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18691650 | IDEBENONE DERIVATIVES AND THEIR USE IN TREATING PLANTS | O DELL, DAVID K | 1621 | §102§112 | Non-Final OA | — | Pending | Mar 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMitorx Therapeutics Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David K O Dell has the most, with 1 of Mitorx Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
